Literature DB >> 21576341

Mouse relapse model of Clostridium difficile infection.

Xingmin Sun1, Haiying Wang, Yongrong Zhang, Kevin Chen, Barbara Davis, Hanping Feng.   

Abstract

Clostridium difficile is the causative agent of primary and recurrent antibiotic-associated diarrhea and colitis in hospitalized patients. The disease is caused mainly by two exotoxins, TcdA and TcdB, produced by the bacteria. Recurrent C. difficile infection (CDI) constitutes one of the most significant clinical issues of this disease, occurs in more than 20% of patients after the first episode, and may be increasing in frequency. However, there is no well-established animal model of CDI relapse currently available for studying disease pathogenesis, prevention, and therapy. Here we report the establishment of a conventional mouse model of recurrence/relapse CDI. We found that the primary episode of CDI induced little or no protective antibody response against C. difficile toxins and mice continued shedding C. difficile spores. Antibiotic treatment of surviving mice induced a second episode of diarrhea, while a simultaneous reexposure of animals to C. difficile bacteria or spores elicited a full spectrum of CDI similar to that of the primary infection. Moreover, mice treated with immunosuppressive agents were prone to more severe and fulminant recurrent disease. Finally, utilizing this model, we demonstrated that vancomycin only delayed disease recurrence, whereas neutralizing polysera against both TcdA and TcdB completely protected mice against CDI relapse. In conclusion, we have established a mouse relapse CDI model that allows for future investigations of the role of the host immune response in the disease's pathogenesis and permits critical testing of new therapeutics targeting recurrent disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576341      PMCID: PMC3191975          DOI: 10.1128/IAI.01336-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

Review 1.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

2.  Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; A Richard; K Hamadi; V Chomette; B Burghoffer; J C Petit
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.

Authors:  S W Pawlowski; G Calabrese; G L Kolling; J Platts-Mills; R Freire; C AlcantaraWarren; B Liu; R B Sartor; R L Guerrant
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

Review 4.  [Epidemiology, risk factors and prevention of Clostridium difficile nosocomial infections].

Authors:  F Barbut; J C Petit
Journal:  Pathol Biol (Paris)       Date:  2000-10

5.  Liver abscess caused by Clostridium difficile.

Authors:  T Sakurai; K Hajiro; H Takakuwa; A Nishi; M Aihara; T Chiba
Journal:  Scand J Infect Dis       Date:  2001

6.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

7.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

8.  Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea.

Authors:  Yajarayma Tang-Feldman; Susan Mayo; Joseph Silva; Stuart H Cohen
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.

Authors:  Lynne V McFarland; Gary W Elmer; Christina M Surawicz
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

10.  Clindamycin-associated enterocolitis in guinea pigs: evidence for a bacterial toxin.

Authors:  F C Knoop
Journal:  Infect Immun       Date:  1979-01       Impact factor: 3.441

View more
  54 in total

1.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

2.  Cwp22, a novel peptidoglycan cross-linking enzyme, plays pleiotropic roles in Clostridioides difficile.

Authors:  Duolong Zhu; Jessica Bullock; Yongqun He; Xingmin Sun
Journal:  Environ Microbiol       Date:  2019-06-28       Impact factor: 5.491

3.  TPL2 Is a Key Regulator of Intestinal Inflammation in Clostridium difficile Infection.

Authors:  Yuanguo Wang; Shaohui Wang; Ciaran P Kelly; Hanping Feng; Andrew Greenberg; Xingmin Sun
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

4.  MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Authors:  Michelle M Butler; Dean L Shinabarger; Diane M Citron; Ciarán P Kelly; Sofya Dvoskin; George E Wright; Hanping Feng; Saul Tzipori; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

5.  Role of GM-CSF in the inflammatory cytokine network that regulates neutrophil influx into the colonic mucosa during Clostridium difficile infection in mice.

Authors:  Andrew J McDermott; Charles R Frank; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Gut Microbes       Date:  2014-07-21

Review 6.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

7.  Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.

Authors:  Zhi Lv; Guoli Peng; Weihua Liu; Hufeng Xu; JianRong Su
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

8.  Using a Novel Lysin To Help Control Clostridium difficile Infections.

Authors:  Qiong Wang; Chad W Euler; Aurelia Delaune; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

9.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

10.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.